ERBB2 and breast carcinoma: To test whether activation of the PAM signaling pathway is responsible for resistance in HER2-positive breast cancer induced by PPARG, we introduced Everolimus, an mTOR inhibitor widely used in studies of PAM signaling pathway inhibition25.